Health Dictionary
Reliable, easy-to-read patient information on common medical conditions — written in plain language, free of jargon, and grounded in current evidence. Browse the most frequent diagnoses, understand what they mean for everyday life, and learn which steps and questions help you have a focused conversation with your doctor.
Thymoma future or investigational therapies
Introduction
Overview
Overview
Due to the advancement in understanding the molecular biology of the disease, there is an increased number of targeted therapies being tested in clinical trials, but the results have so far been disappointing.
Targeted Therapy
Targeted Therapy
- KIT pathway
- It is overexpressed by immunohistochemistry in 2% of thymomas and in 79% of thymic carcinomas. Imatinib and nilotinib are been tried in several clinical trials.[1]
- Epidermal growth factor pathway
- IGF-1R pathway
- Expression of IGF-1R was found in 4% of thymomas and in 37% of thymic carcinomas. Figitumumab and cixutumumab have been tried in different clinical trials.[3]
References
References
- ↑ Ströbel, P.; Hartmann, M.; Jakob, A.; Mikesch, K.; Brink, I.; Dirnhofer, S.; Marx, A. (2004). “Thymic carcinoma with overexpression of mutated KIT and the response to imatinib”. N Engl J Med. 350 (25): 2625–6. doi:10.1056/NEJM200406173502523. PMID 15201427. Unknown parameter
|month=ignored (help) - ↑ Farina, G.; Garassino, MC.; Gambacorta, M.; La Verde, N.; Gherardi, G.; Scanni, A. (2007). “Response of thymoma to cetuximab”. Lancet Oncol. 8 (5): 449–50. doi:10.1016/S1470-2045(07)70141-9. PMID 17466903. Unknown parameter
|month=ignored (help) - ↑ Kelly, RJ.; Petrini, I.; Rajan, A.; Wang, Y.; Giaccone, G. (2011). “Thymic malignancies: from clinical management to targeted therapies”. J Clin Oncol. 29 (36): 4820–7. doi:10.1200/JCO.2011.36.0487. PMID 22105817. Unknown parameter
|month=ignored (help)
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Amr Marawan, M.D. [2]